0001562180-22-005001.txt : 20220610
0001562180-22-005001.hdr.sgml : 20220610
20220610081154
ACCESSION NUMBER: 0001562180-22-005001
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220608
FILED AS OF DATE: 20220610
DATE AS OF CHANGE: 20220610
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Spellman David A
CENTRAL INDEX KEY: 0001733204
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36352
FILM NUMBER: 221007679
MAIL ADDRESS:
STREET 1: 840 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Akebia Therapeutics, Inc.
CENTRAL INDEX KEY: 0001517022
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 208756903
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 245 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-871-2098
MAIL ADDRESS:
STREET 1: 245 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2022-06-08
false
0001517022
Akebia Therapeutics, Inc.
AKBA
0001733204
Spellman David A
C/O AKEBIA THERAPEUTICS, INC.
245 FIRST STREET
CAMBRIDGE
MA
02142
false
true
false
false
SVP, CFO and Treasurer
Common Stock
2022-06-08
4
A
false
200000.00
0.00
A
328599.00
D
Stock Option (Right to buy)
0.45
2022-06-08
4
A
false
200000.00
0.00
A
2023-05-12
2032-06-08
Common Stock
200000.00
200000.00
D
The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended (the "2014 Plan"). The RSUs will vest in full (100%) on May 12, 2023, subject to the Reporting Person's continued service with the Issuer on such vesting date.
The option to purchase shares of the Issuer's common stock ("the Stock Option") was granted by the Issuer pursuant to the 2014 Plan. The Stock Option will vest and become exercisable in full (100%) on May 12, 2023, subject to the Reporting Person's continued service with the Issuer on such vesting date.
/s/ Carolyn Rucci, attorney-in-fact for David A. Spellman
2022-06-10